News und Analysen
QuidelOrtho Reports Fourth Quarter and Full-Year 2024 Financial Results
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and
Royal Gold Concludes an Outstanding Year of Financial Performance with Records for Revenue, Operating Cash Flow and Earnings for both the Fourth Quarter and the Full Year of 2024
Royal Gold, Inc. (NASDAQ: RGLD) (together with its subsidiaries, “Royal Gold,” the “Company,” “we,” “us,” or “our”) reports net income of $332.0 million, or $5.04 per share, for the year ended
Martin Midstream Partners Reports Fourth Quarter and Full Year 2024 Financial Results and Releases 2025 Guidance
Martin Midstream Partners L.P. (Nasdaq: MMLP) (“MMLP” or the “Partnership”) today announced its financial results for the fourth quarter and full year ended December 31, 2024.
Bob Bondurant
Ventas Reports 2024 Full Year Results, Provides 2025 Outlook and Increases Dividend
Ventas, Inc. (NYSE: VTR) (“Ventas” or the “Company”) today reported results for the full year and fourth quarter ended December 31, 2024.
CEO Remarks
“Ventas delivered strong financial
CI Financial Obtains Shareholder Approval for Plan of Arrangement with Mubadala Capital
CI Financial Corp. (“CI” or the “Corporation”) (TSX:CIX) announced that at the special meeting of shareholders held earlier today, an overwhelming majority of CI shareholders voted in favour of the
U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS® (brentuximab vedotin) in
U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS® (brentuximab vedotin) in
Philip Morris International to Present at 2025 CAGNY Conference
Regulatory News:
Philip Morris International Inc. (PMI) (NYSE: PM) will host a live audio webcast of a presentation by Jacek Olczak, Chief Executive Officer, and Emmanuel Babeau, Chief Financial
Eastman CEO Mark Costa to Address the Barclays Industrial Select Conference
Eastman Chemical Company (NYSE:EMN):
Industrial Select Conference
Mark Costa, Board Chair and Chief Executive Officer, Eastman Chemical Company (NYSE:EMN), will address the Barclays 42nd
FIGEAC AÉRO: FINANCIAL CALENDAR
EQS-News: wienerberger is strongly committed to a shareholder value-orientated capital allocation strategy and cancels 2% of its share capital
Union Pacific Corporation Executives to Address Barclays 2025 Industrial Select Conference
Jim Vena, chief executive officer, Jennifer Hamann, executive vice president and chief financial officer, and Kenny Rocker, executive vice president – Marketing & Sales, of Union Pacific
ServiceNow Launches Government Transformation Suite, Uniting High-Impact Solutions Tailored to Administration Priorities
SERVICENOW FEDERAL FORUM – ServiceNow (NYSE: NOW), the AI platform for business transformation, today launched the new Government Transformation Suite to increase visibility, accelerate ROI, and
The Typical Homebuyer Pays Roughly 2% Less than the List Price–The Biggest Discount in 2 Years
(NASDAQ: RDFN) — Today’s average home listing is selling for under its asking price, and taking a long time to sell, according to a new report from Redfin (redfin.com), the technology-powered real
HCSG Reports Q4 2024 Results
Healthcare Services Group, Inc. (NASDAQ:HCSG) today reported results for the three months ended December 31, 2024.
Ted Wahl, Chief Executive Officer, stated, “2024 was a transitional year for
CI Global Asset Management Announces February 2025 Distributions for the CI ETFs
CI Global Asset Management (“CI GAM”) announces the following regular cash distributions for the month ending February 28, 2025 in respect of the CI ETFs. In all cases, the distribution will be
Exelon Reports Fourth Quarter and Full Year 2024 Results and Initiates 2025 Financial Outlook
Exelon Corporation (Nasdaq: EXC) today reported its financial results for the fourth quarter and full year 2024.
"I am pleased to announce Exelon has delivered against our financial goals for
Exelon Reports Fourth Quarter and Full Year 2024 Results and Initiates 2025 Financial Outlook
Exelon Corporation (Nasdaq: EXC) today reported its financial results for the fourth quarter and full year 2024.
"I am pleased to announce Exelon has delivered against our financial goals for
Director Declaration
EQS-News: PVA TePla with slight sales growth and robust earnings increase in 2024
EQS-News: Significant EBITDA recovery in Q2 2024/25 compared to previous quarter
EQS-News: Significant EBITDA recovery in Q2 2024/25 compared to previous quarter
EQS-News: Strong FY 2024 performance: Revenue up by 9 % YoY and exceeded guidance range, Enterprise Revenue grows by 26 % YoY, and Adjusted EBITDA Margin reaches 44 %



